Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.
about
The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.Anti-GD2 immunotherapy for neuroblastoma.Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, anA phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.CAR T Cell Therapy for Neuroblastoma
P2860
Q33643120-AEC76BEB-46ED-448E-901C-6A7381E11B5CQ38608663-0669213B-C400-45CC-B354-B4AD9352660DQ38716908-5C61A0B0-3D10-485A-A56E-5AC6C30EC496Q40041609-2880141E-9E77-4E74-AC29-C891D1312189Q46091824-66303F9C-6C6F-48EA-B3D8-D104C3D7487FQ47108370-9033241D-21DE-47D1-BD03-02877AC4A477Q47176287-78619114-860F-4D8C-8134-18AC8B7BAC49Q47554435-7C76809A-2AB2-46E8-9622-C4C6021B5FA7Q50523001-E5FEC9FE-0657-4A35-BBC4-7FECF2A22012Q51483438-E68D631B-31F8-414F-A4B3-F1410B34C3F0Q59127901-B61F0523-31AA-46D9-A765-49FE136ABE95
P2860
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prolonged progression-free sur ...... a prospective Phase II study.
@ast
Prolonged progression-free sur ...... a prospective Phase II study.
@en
type
label
Prolonged progression-free sur ...... a prospective Phase II study.
@ast
Prolonged progression-free sur ...... a prospective Phase II study.
@en
prefLabel
Prolonged progression-free sur ...... a prospective Phase II study.
@ast
Prolonged progression-free sur ...... a prospective Phase II study.
@en
P2093
P2860
P50
P1433
P1476
Prolonged progression-free sur ...... a prospective Phase II study.
@en
P2093
Brian H Kushner
Irene Y Cheung
Irina Ostrovnaya
Kim Kramer
N K Cheung
P2860
P304
P356
10.1080/2162402X.2015.1016704
P577
2015-05-22T00:00:00Z